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Objectives The aim of this study was to evaluate the effect of high-dose allopurinol on vascular oxidative stress (OS) and
endothelial function in subjects with stable coronary artery disease (CAD).
Background Allopurinol, a xanthine oxidase inhibitor, prolongs the time to chest pain during exercise in angina. We sought to
ascertain whether allopurinol also improves endothelial dysfunction in optimally treated CAD patients, because
such an effect might be of value to reduce future cardiovascular mortality. The mechanism of the anti-ischemic
effect of allopurinol could be related to its reducing xanthine oxidase-induced OS, and our second aim was to
see whether allopurinol really does reduce vascular tissue OS in CAD patients.
Methods A randomized, double-blind, placebo-controlled, crossover study was conducted in 80 patients with CAD, compar-
ing allopurinol (600 mg/day) with placebo. Endothelial function was assessed by forearm venous occlusion
plethysmography, flow-mediated dilation, and pulse wave analysis. Vascular OS was assessed by intra-arterial
co-infusion of vitamin C and acetylcholine.
Results Compared with placebo, allopurinol significantly improved endothelium-dependent vasodilation, by both forearm
venous occlusion plethysmography (93  67% vs. 145  106%, p  0.006) and flow-mediated dilation (4.2 
1.8% vs. 5.4  1.7%, p  0.001). Vascular oxidative stress was completely abolished by allopurinol. Central aug-
mentation index improved significantly with allopurinol (2.6  7.0%, p  0.001) but not with placebo.
Conclusions Our study demonstrates that, in optimally treated CAD patients, high-dose allopurinol profoundly reduces vascu-
lar tissue OS and improves 3 different measures of vascular/endothelial dysfunction. The former effect on OS
might underpin the anti-ischemic effect of allopurinol in CAD. Both effects (on OS and endothelial dysfunction)
increase the likelihood that high-dose allopurinol might reduce future cardiovascular mortality in CAD, over and
above existing optimum therapy. (Exploring the therapeutic potential of xanthine oxidase inhibitor allopuri-
nol in angina; ISRCTN15253766) (J Am Coll Cardiol 2011;58:820–8) © 2011 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.12.052High-dose allopurinol has recently been shown to mark-
edly prolong the time to chest pain and to ST-segment
depression during exercise in patients with chronic stable
angina (1). This might be related to previous experimen-
tal work suggesting that allopurinol somehow reduces
myocardial oxygen consumption for a given stroke
volume (2– 4). Two key questions naturally arise from
this. First, what is the mechanism in man whereby
allopurinol delays chest pain during exercise? Second,
will this anti-ischemic symptomatic benefit translate
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2010, accepted December 7, 2010.into allopurinol also improving survival in angina? Our
study was designed to shed light on both of these key
questions.
See page 829
With regard to the first question, work in experimental
heart failure shows that the main xanthine oxidase
(XO)-related factor that influences myocardial oxygen
consumption is oxidative stress (OS) (5). If allopurinol
really does reduce XO-induced OS in human angina,
then such an effect could well contribute to its anti-chest
pain effect (6). Yet, there are currently no data (in animals
or man) on whether allopurinol really does reduce OS in
coronary artery disease (CAD). Furthermore, even if it
does usually reduce OS, does it still do so in the presence
of full contemporary CAD therapy.
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August 16, 2011:820–8 Xanthine Oxidase, Oxidative Stress, and AnginaWith regard to the second question posed, we also sought to
gain insight into whether allopurinol might also one day
improve survival in CAD. Overall survival is not usually
improved in angina by treatments that improve symptoms (e.g.,
itrates, amlodipine, angioplasty), aside from beta-blockers.
mproved survival in CAD is usually produced instead by drugs
hat reduce plaque formation and instability by multiple mech-
nisms, including by reducing endothelial dysfunction (ED)
e.g., statins and angiotensin-converting enzyme [ACE] inhibi-
tors). We therefore sought also to see whether allopurinol
improved ED in optimally treated CAD patients to gain
insight into whether there is any prospect that allopurinol
might also improve survival in CAD.
One particularly relevant issue here is the contemporary
treatment that CAD patients nowadays receive. This is be-
cause there is a strong possibility that treatments like statins
and ACE inhibitors might already have so improved ED that
targeting XO to further improve ED could be futile (7–10). As
an example of this possibility, the negative results of the
PEACE (Prevention of Events with Angiotensin Converting
Baseline Characteristics of SubjectsTable 1 Baseline Characteristics of Subjects
Total no. of subjects (M/F) 80 (64/16)
Age (yrs) 65.5 7.73
No. of vessels diseased (1/2/3) 17/30/33
CCS class (1/2/3) 58/22/0
Medical treatment/PCI/CABG 11/47/22
Current smoker/ex-smoker/nonsmoker 11/26/43
Past medical history
Hypertension 31 (39)
Hypercholesterolemia 58 (74)
Previous myocardial infarction 21 (26)
Diabetes mellitus 7 (9)
Medications
ASA/clopidogrel 80 (100)
ACE inhibitor/ARB 68 (85)
Ramipril equivalent dose, average (mg) 7.35
Beta-blockers 60 (75)
Statins 76 (95)
Simvastatin equivalent dose, average (mg) 37
Thiazide diuretics 9 (11)
Nitrate 21 (26)
Biochemical and hemodynamic data
Na (mmol/l) 141 2.1
K (mmol/l) 4.5 0.3
Urea (mg/dl) 16.8 4.2
Creatinine (mg/dl) 1.08 0.15
Total cholesterol (mg/dl) 150.8 31.5
Creatinine clearance (ml/min) 78 25
Heart rate (beats/min) 61 10
SBP (mm Hg) 132 12
DBP (mm Hg) 75 8
MAP (mm Hg) 93 8
Values are n, mean  SD, or number of medications (percentage of patients).
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; ASA  acetyl
salicylic acid; CABG  coronary artery bypass graft surgery; CCS  Canadian Cardiovascularh
Society; DBP  diastolic blood pressure; K  potassium; MAP  mean arterial pressure; Na 
sodium; PCI  percutaneous coronary intervention; SBP  systolic blood pressure.Enzyme Inhibition) trial might
have been because the ED of pa-
tients had been so improved al-
ready by statin therapy as to make
ACE inhibitors ineffective. There-
fore, a novel feature of our study
was that we studied only optimally
treated CAD patients to see
whether XO inhibition can still
improve ED and XO-induced OS
in the presence of optimal CAD
co-treatment. Only if allopurinol
gives added value over contempo-
rary treatment is it likely to be of
practical therapeutic use.
Methods
Study population. Ninety con-
secutive patients with angio-
graphically proven CAD (luminal
stenosis of at least 50%) and pre-
served left ventricular systolic
function (determined by either
echocardiogram or left ventriculo-
gram) were identified from cardi-
ology clinics and an angiogram database within a period of just
12 months. Baseline characteristics are noted in Table 1.
Single vessel disease was present in 17 of 80, double vessel
disease was present in 30 of 80, and triple vessel disease was
present in 33 of 80. Approximately 85% of the subjects had
undergone successful revascularization in the past. However,
coronary revascularization had obviously not directly altered
the arm blood vessels we were studying. The following were
exclusion criteria: unstable angina (last 3 months), cardiac
failure, malignancy, use of warfarin or allopurinol, chronic
kidney disease stage 4 or worse, hypertension (systolic blood
pressure160 mm Hg and diastolic blood pressure100 mm
g), and allopurinol allergy. All patients provided written
nformed consent, and the study was approved by the Tayside
ommittee on medical research ethics. The study was con-
ucted in accordance with the Declaration of Helsinki.
tudy protocol. This was a randomized, double-blind,
lacebo-controlled, crossover trial, with a 4-week washout
etween treatments (Fig. 1). After initial screening, subjects
ere randomized to receive either allopurinol (Ranbaxy
reland, Ltd., Tipperary, Ireland) or matching placebo
Penn Pharmaceutical Services, Tredegar, Wales) for 8
eeks. Randomization was done by using an Internet
rogram, and subjects were randomized to receive either
reatment A or B (allopurinol or placebo) first. Randomiza-
ion code was kept sealed in the department. Investigators
nd patients were blinded to the order of the treatment they
eceived. The dose of allopurinol was 300 mg for 4 weeks
nd 600 mg for 4 weeks with a 4-weekly check on
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
Ach  acetylcholine
AIx  augmentation index
CAD  coronary artery
disease
CI  confidence interval
CV  cardiovascular
ED  endothelial
dysfunction
FBFR  forearm blood flow
ratio
FMD  flow-mediated
dilation
NO  nitric oxide
OS  oxidative stress
Ox-LDL  oxidized low-
density lipoprotein
SNP  sodium
nitroprusside
XO  xanthine oxidaseematology and biochemistry.
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Xanthine Oxidase, Oxidative Stress, and Angina August 16, 2011:820–8Forearm venous occlusion plethysmography. Forearm ve-
nous occlusion plethysmography was performed at the end of
each treatment, and our protocol has been published previously
(6,11,12). Acetylcholine (Ach) (25, 50, and 100 nmol/min,
Novartis, Basel, Switzerland) was first infused, followed after
washout by sodium nitroprusside (SNP) (Mayne Pharma,
Figure 1 Study Design
Schematic representation of study design and flow. FMD  flow-mediated dilation;Leamington, Warks, United Kingdom) at 37.8 nmol/min.Thereafter, to study OS, vitamin C 25 mg/ml (ascorbic acid,
UCB Pharma, Ltd., Slough, United Kingdom) was coinfused
with Ach 25, 50, and 100 nmol/min.
Flow-mediated dilation. Flow-mediated dilation (FMD)
was performed at the beginning and the end of each
treatment. The FMD has been described by us previously
 forearm venous occlusion plethysmography; PWA  pulse wave analysis.FVOPaccording to international guidelines (13,14).
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August 16, 2011:820–8 Xanthine Oxidase, Oxidative Stress, and AnginaAugmentation index. Central augmentation index (AIx)
corrected to a heart rate of 75 beats/min was determined by
pulse wave analysis as previously described in 39 patients at
the beginning and the end of each treatment (15). All
vascular studies were performed and analyzed by a single
trained investigator (N.S.R.).
Laboratory tests. Blood was collected at baseline and at the
end of each treatment after 30 min of supine rest. B-type
natriuretic peptide (Bachem, Ltd., St. Helens Merseyside,
United Kingdom), uric acid (colorimetric assay, Cobas Bio,
Roche, Lewes, United Kingdom), and procollagen 3-N
terminal peptide (radioimmunoassay, Oxford Biosystems,
Oxford, United Kingdom) were analyzed at the end of the
study. Oxidized low-density lipoprotein (Ox-LDL) levels
were measured by a Mercodia Ox-LDL enzyme-linked
immunoadsorbent assay kit, and plasma levels of F2-
isoprostanes were measured by gas chromatography–mass
spectrometry. We standardized to the isoprostane 8-epi-
PGF2-alpha with 2,4-tetra-D2-8-epiprostaglandin F2-
alpha as internal standard.
Statistical analysis. The sample size was based on a mean
forearm blood flow ratio (FBFR) of 263 when Ach 100 was
infused, as seen previously by us. To detect a 20% change
with an SD of difference of 166, we needed 79 completers
to have 80% power at p  0.05.
Data were analyzed for normal distribution and presented
as mean  SD. Data were analyzed for any carryover effect
by comparing the baselines and for sequence effect by
testing for interaction of on-treatment change. Paired t test
r Wilcoxon signed rank test was used as appropriate.
orearm blood flow values (expressed as ml/min/100 ml
orearm tissue) were converted to ratio (the ratio of increase
n blood flow in infused arm to control arm, FBFR) and
ercentage increase in FBFR from preceding baseline (ab-
olute ratio). The data were analyzed by repeated measures
nalysis of variance with Bonferroni method for calculating
5% confidence interval (CI), with treatment and order of
nfusion as fixed factors, and patient number as the random
actor. A 2-tailed p value of 0.05 was the criterion for
tatistical significance. Analyses were carried out with SPSS
or Windows (version 12.0, SPSS, Inc., Chicago, Illinois).
Effect of Allopurinol and Placebo on EndothelialFun i n, Ser m Ur te, and Serum BiomarkersTable 2 Effect of Allopurinol a d Placebo on EndothelialFunction, Serum Urate, and Serum Biomarkers
Parameter, n Allopurinol Placebo p Value
FMD, % (n  76) 5.4 1.7 4.1 1.8 0.001
AIx, % (n  39) 24.7 4.6 27.6 5.5 0.001
Urate, mg/dl (n  77 ) 2.54 0.84 5.76 1.18 0.001
BNP, pg/dl (n  74) 52.8 2.3 69.3 2.5 NS
PIIINP, mg/l (n  72) 3.44 (0.97) 3.35 (0.88) NS
CrCl, ml/min 83 28 82 27 NS
Ox-LDL, U/l 48.9 1.8 57.3 4 0.01
F2-Isoprostanes, pg/ml 240 93 259 113 0.09
AIx  augmentation index; BNP  B-type natriuretic peptide; CrCl  creatinine clearance; FMD t
ow-mediated dilation; Ox-LDL  oxidized low-density lipoprotein; PIIINP  procollagen 3-N
erminal peptide.Results
Of the 90 patients recruited, 80 completed the study (Table 1).
Allopurinol was well tolerated with no adverse events
reported. In particular, there were no reports of rash or
worsening renal function (Table 2). Six patients dropped
out, citing personal reasons; 1 was admitted with troponin
negative angina (taking allopurinol); 2 gave no reason; and
1 patient dropped out, due to generalized malaise, while
taking placebo.
Forearm venous occlusion plethysmography. BASAL
LOWS, WASHOUTS, AND BLOOD PRESSURE. Baseline
FBFR did not differ between allopurinol and placebo (p 
0.493). Also, no significant difference in FBFR was appar-
ent for washouts after infusing Ach and SNP either within
a treatment phase or between allopurinol and placebo.
Systemic blood pressure and heart rate did not vary between
the baseline and washout periods.
RESPONSE TO ACH, SNP, AND VITAMIN C COINFUSIONWITH
ACH. There was a significant 52% increase in endothelium-
ependent vasodilation with allopurinol, compared with
lacebo (p  0.006) (Fig. 2).
When vitamin C was coinfused with Ach, there was a
ighly significant increase in FBFR only during placebo
p  0.001) but not during allopurinol (p  0.386) (Fig. 3).
MD. Allopurinol increased brachial artery FMD highly
ignificantly from a baseline of 4.2  1.8% to 5.4  1.7%
95% CI: 1.18 to 1.42, p  0.001), whereas placebo did not
roduce any change (4.2  1.8% to 4.1  1.8%, 95% CI:
1.12 to 1.08, p  0.76) (Fig. 4).
Ix. Allopurinol significantly reduced central AIx cor-
ected to heart rate of 75 beats/min, from 27.3  5.0% to
4.7  4.6% (95% CI: 0.41 to 4.84, p  0.001), whereas
here was no significant change with placebo (27.8  5.9%
o 27.6  5.5%, 95% CI: 2.4 to 2.64, p  1.0) (Fig. 5).
iochemistry and biomarkers. Allopurinol significantly
educed Ox-LDL levels (57.3  4 U/l vs. 48.9  1.8 U/l;
 0.01) and was associated with lower levels of F2-
soprostanes, compared with placebo, although this failed to
each statistical significance (240  93 pg/ml vs. 259  113
g/ml; p 0.09) (Table 2). B-type natriuretic peptide levels
id fall on allopurinol, although the results fell short of
tatistical significance.
iscussion
his study has 3 main findings. The first is that, despite full
ptimum therapy, CAD patients still exhibit marked vas-
ular OS (i.e., intra-arterial high-dose vitamin C improves
ascular responses to Ach by 100% during placebo). Our
econd finding is that endogenous XO is a major source of
his vascular tissue OS as well as of widespread vascular
ysfunction. Our third finding is that XO inhibition pro-
oundly improves both vascular tissue OS and widespread
ascular dysfunction in CAD patients who are already
aking optimal CAD therapy.
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Xanthine Oxidase, Oxidative Stress, and Angina August 16, 2011:820–8The clinical implications of our results are 2-fold.
Firstly, because XO-induced OS is associated with in-
creased myocardial oxygen consumption in animal stud-
ies, our finding that allopurinol profoundly decreases
XO-induced OS in treated CAD patients could well
contribute mechanistically to the recently observed anti-
ischemic effect of allopurinol in patients with stable
angina (1). Part of the reason for this could be that
olecular oxygen is a substrate for XO, meaning that
ndogenous XO activity effectively reduces the supply of
xygen to ischemic tissue (16). In fact, XO is known to
Figure 2 Endothelial Function
Forearm blood flow ratio (FBFR) data for placebo versus allopurinol (mean  SEM)
(A) Acetylcholine (25, 50, and 100 nmol/min); (B) sodium nitroprusside (37.8 nmonsume a lot of oxygen not only because it producessuperoxide anions and hydrogen peroxide but also because
the main XO substrate (hypoxanthine) has only 1 oxygen/
molecule, whereas the main XO product, uric acid, has 3.
Thus, XO-induced OS might not be a culprit per se but
instead could be a marker that precious molecular oxygen is
being “wasted” (by XO) in producing OS. If this were the
case, this might also be a novel explanation for why OS
often seems to be a culprit but neutralizing OS with
antioxidant vitamins has been disappointing. A whole
alternative explanation, of course, is that XO-induced OS is
itself a culprit, able by itself to increase tissue oxygen
n).
.
ol/miconsumption, as some data suggest (5).
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August 16, 2011:820–8 Xanthine Oxidase, Oxidative Stress, and AnginaThe second clinical implication follows from our demon-
stration that allopurinol markedly improves endothelial/
vascular dysfunction in CAD. This raises the separate
possibility that allopurinol might improve survival in CAD.
In fact, dysfunction in all 3 of our measures of endothelial/
vascular function are each independently linked with prog-
nosis, and therefore it is particularly promising that allo-
purinol improved all 3, although clearly not all therapies
that improve endothelial function always benefit hard clin-
ical endpoints (17–20). It is also true that no other therapy
Figure 3 Vascular Oxidative Stress
Forearm blood flow ratio (FBFR) data (mean  SEM) for acetylcholine (25, 50, and
acetylcholine  vitamin C (25 mg/ml) for placebo (A) and allopurinol (B)—an in vhas consistently improved 3 different measures of vasculardysfunction: improvement in 1 or 2 but not 3 is common
(21). Furthermore, the effect of allopurinol on OS could also
be relevant here, because vascular OS—as measured by the
vitamin C technique used here—is also known to predict
cardiovascular (CV) events independently of endothelial
function: indeed, vascular OS seems to be an even better
predictor of future CV events than endothelial function per
se (22). This might be because OS is thought to contribute
particularly to plaque instability (23). Therefore, overall, it
could turn out that allopurinol will improve both the time to
mol/min) alone versus
asure of vascular oxidative stress.100 n
ivo mechest pain during exercise and the number of future (CV)
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Xanthine Oxidase, Oxidative Stress, and Angina August 16, 2011:820–8deaths. The former has already been demonstrated (1). The
latter is at this point in time only a hopeful prospect, but its
likelihood is reinforced by our data on ED and OS as well
as by 2 large observational studies where the use of allopuri-
nol was associated in both studies with a highly significant
reduction in total mortality (22% reduction in 1 study, and
a 26% reduction in the other) (24,25). If so, allopurinol
could turn out to be the only antianginal, other than
beta-blockers, that improves both symptoms and survival—
which would elevate allopurinol into not just being yet
another antianginal.
The vitamin C technique we used here to assess vascular
OS is a well-established technique (6,22,26,27) with 3 main
advantages over blood or urine OS biomarkers: it measures
function rather than just levels, it reflects vascular tissues
Figure 4 Flow-Mediated Dilation
Effect of allopurinol and placebo on brachial artery flow-mediated dilation (FMD) (Arather than just blood or urine, and it is an in vivo measurerather than an ex vivo or in vitro measure. Indeed, plasma or
urine biomarkers for OS have their limitations in therapeu-
tic studies (28): for example, successful therapies like statins
do not produce consistent changes in very many OS biomark-
ers (29,30). Because we were mainly interested here in vascular
OS rather than circulating OS, the vitamin C technique is the
gold standard in our study. The dose of vitamin C we used (25
mg/ml) is extremely high and effectively much higher than
used in any large antioxidant clinical trial. When co-infused
with Ach, high-dose parenteral vitamin C enhances vasodila-
tion, because it reduces the vascular OS that would normally
degrade endogenous nitric oxide (NO). Therefore, if there
were to be no OS, then vitamin C would not have any
enhancing effect on Ach-mediated vasodilation, which is ex-
actly what we found in the presence of high-dose allopurinol.
response to glyceryl trinitrate (B).) andAn important point is that we previously saw the same large
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August 16, 2011:820–8 Xanthine Oxidase, Oxidative Stress, and Anginaeffect on vascular OS in heart failure patients, which adds
credibility to our results here (6).
A recognized disadvantage of using vitamin C in this way
is the concern that the results obtained can sometimes be
because the blood vessels have reached their vasodilatory
ceiling, but this cannot be the case here because both SNP
and the top-dose Ach/vitamin C response with placebo
produced a higher absolute FBFR than when allopurinol
was administered.
The magnitude of the effect against vascular tissue OS is
so large here and in our previous congestive heart failure
study that it becomes possible that allopurinol reduces OS
by mechanisms additional to XO inhibition, although no
such extra mechanism has yet been identified (6). Even if
some additional mechanism is involved, this does not
detract from the strong therapeutic potential for high-dose
allopurinol in CAD. Another explanation for such a large
effect of allopurinol here is that endogenous XO activity is
up-regulated in ischemic tissue (31). A third explanation for
the magnitude of the effect seen here is the high dose of
allopurinol used, which incidentally matched the high dose
that we found to be anti-ischemic (1).
Ox-LDL is not a unique chemical entity, and therefore
different assays detect different epitopes in this complex
molecule. Therefore, each assay has limitations, including
ours—which mainly measures oxidized apolipoprotein-B
(28). However, our Ox-LDL results are corroborated by
Tsutsumi et al. (32), who found in gout that allopurinol
significantly reduced Ox-LDL with a completely different
Figure 5 Augmentation Index
Effect of allopurinol and placebo on central augmentation index, corrected to hearassay. Other factors increase the credibility of our Ox-LDL aresults. First, they agree with our main vitamin C results on
vascular OS. Second, they agree with our p  0.09 reduc-
ion in isoprostanes. Third, they agree with much previously
ublished data that allopurinol reduces another OS bio-
arker, malondialdehyde (11,12). Fourth, Tsutsumi et al.
32) found that allopurinol reduced Ox-LDL but did not
hange low-density lipoprotein cholesterol itself, and it is
hanges in the latter that are the main confounder with our
x-LDL assay (32). In any case, the Ox-LDL results are
erely corroborative here, because our study was primarily
esigned to measure vascular tissue OS, which might not
ecessarily correlate with all plasma OS biomarkers, because
ach one assesses different aspects of circulating OS.
It is worth saying that it is at least plausible that the
owering of uric acid per se could have contributed directly
o the improvement in endothelial function and in OS that
e saw. This follows from recent observations that uric acid
an activate OS in vitro (33).
A minor weakness of our study is that we were unable to
ssess in vivo whether the improved endothelial function
as definitely due to NO or not. Neither NG-monomethyl-
-arginine nor nitrite measurements would have been
nformative here, because both mainly reflect NO synthesis,
hereas allopurinol probably acts primarily on the inactiva-
ion of already formed NO. By contrast, our study has many
trengths, such as clear-cut results for all vascular measures,
he use of the gold standard invasive technique for assessing
ascular tissue OS, and the magnitude of the effect seen in
(HR) of 75 beats/min.t ratell vascular parameters. Another strength is that we used 3
828 Rajendra et al. JACC Vol. 58, No. 8, 2011
Xanthine Oxidase, Oxidative Stress, and Angina August 16, 2011:820–8complementary methods to assess endothelial function,
whereas most studies use 1 or at most 2 such methods.
Conclusions
Despite full contemporary treatment in CAD patients,
vascular OS remains marked, and endogenous XO is a
major source of it. As a result, allopurinol profoundly
reduces both vascular OS and 3 separate measures of ED in
CAD. The former effect could underpin the recently dem-
onstrated anti-ischemic effect of allopurinol in angina (1).
These results (on OS and ED) also raise the prospect that
allopurinol might reduce future CV events and deaths in
CAD, especially because OS is thought to contribute to
plaque instability and also because allopurinol is already
associated with a significantly better total mortality in 2
large observational studies (24,25).
Reprint requests and correspondence: Dr. Narasimharajapura
Rajendra, Centre for Cardiovascular and Lung Biology, Division
of Medical Sciences, University of Dundee, Mail Box 2, Ninewells
Hospital and Medical School, Dundee DD1 9SY, United King-
dom. E-mail: drrajendra_ns@rediffmail.com.
REFERENCES
1. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high
dose allopurinol on exercise in patients with chronic stable angina: a
randomised, placebo controlled, crossover trial. Lancet 2010;375:
2161–7.
2. Ekelund UE, Harrison RW, Shokek O, et al. Intravenous allopurinol
decreases myocardial oxygen consumption and increases mechanical
efficiency in dogs with pacing-induced heart failure. Circ Res 1999;
85:437–45.
3. Ukai T, Cheng CP, Tachibana H, et al. Allopurinol enhances the
contractile response to dobutamine and exercise in dogs with pacing-
induced heart failure. Circulation 2001;103:750–5.
4. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves
myocardial efficiency in patients with idiopathic dilated cardiomyop-
athy. Circulation 2001;104:2407–11.
5. Saavedra WF, Paolocci N, St. John ME, et al. Imbalance between
xanthine oxidase and nitric oxide synthase signaling pathways under-
lies mechanoenergetic uncoupling in the failing heart. Circ Res
2002;90:297–304.
6. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose
allopurinol improves endothelial function by profoundly reducing
vascular oxidative stress and not by lowering uric acid. Circulation
2006;114:2508–16.
7. Landmesser U, Spiekermann S, Preuss C, et al. Angiotensin II induces
endothelial xanthine oxidase activation: role for endothelial dysfunc-
tion in patients with coronary disease. Arterioscler Thromb Vasc Biol
2007;27:943–8.
8. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of
atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol
2002;22:300–5.
9. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme
A reductase inhibitor, improves endothelial function within 1 month.
Circulation 1997;95:1126–31.
10. van der Giet M, Erinola M, Zidek W, Tepel M. Captopril and
quinapril reduce reactive oxygen species. Eur J Clin Invest 2002;32:
732–7.
11. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol
normalizes endothelial dysfunction in type 2 diabetics with mild
hypertension. Hypertension 2000;35:746–51.
12. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopuri-
nol improves endothelial dysfunction in chronic heart failure. Circu-
lation 2002;106:221–6.13. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD.
Vitamin D improves endothelial function in patients with type 2
diabetes mellitus and low vitamin D levels. Diabet Med 2008;25:
320–5.
14. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the
ultrasound assessment of endothelial-dependent flow-mediated vaso-
dilation of the brachial artery: a report of the International Brachial
Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257–65.
15. Dawson A, Davies JI, Morris AD, Struthers AD. B-type natriuretic
peptide is associated with both augmentation index and left ventricular
mass in diabetic patients without heart failure. Am J Hypertens
2005;18:1586–91.
16. McCord JM. Oxygen-derived free radicals in postischemic tissue
injury. N Engl J Med 1985;312:159–63.
17. Heitzer T, Baldus S, von Kodolitsch Y, Rudolph V, Meinertz T.
Systemic endothelial dysfunction as an early predictor of adverse
outcome in heart failure. Arterioscler Thromb Vasc Biol 2005;25:
1174–9.
18. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic
endothelial dysfunction in patients with acute coronary syndromes:
further evidence for the existence of the “vulnerable” patient. Circu-
lation 2004;110:1926–32.
19. Karatzis EN, Ikonomidis I, Vamvakou GD, et al. Long-term prog-
nostic role of flow-mediated dilatation of the brachial artery after acute
coronary syndromes without ST elevation. Am J Cardiol 2006;98:
1424–8.
20. Zoungas S, Asmar RP. Arterial stiffness and cardiovascular outcome.
Clin Exp Pharmacol Physiol 2007;34:647–51.
21. Payne RA, Wilkinson IB, Webb DJ. Arterial stiffness and hyperten-
sion: emerging concepts. Hypertension 2010;55:9–14.
22. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial
dysfunction, oxidative stress, and risk of cardiovascular events in
patients with coronary artery disease. Circulation 2001;104:2673–8.
23. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS.
Reactive oxygen species produced by macrophage-derived foam cells
regulate the activity of vascular matrix metalloproteinases in vitro.
Implications for atherosclerotic plaque stability. J Clin Invest 1996;98:
2572–9.
24. Luk AJ, Levin GP, Moore EE, Zhou XH, Kestenbaum BR, Choi
HK. Allopurinol and mortality in hyperuricaemic patients. Rheuma-
tology (Oxford) 2009;48:804–6.
25. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol
use, and heart failure outcomes. Arch Intern Med 2010;170:1358–64.
26. Hirooka Y, Eshima K, Setoguchi S, Kishi T, Egashira K, Takeshita A.
Vitamin C improves attenuated angiotensin II-induced endothelium-
dependent vasodilation in human forearm vessels. Hypertens Res
2003;26:953–9.
27. Spiekermann S, Landmesser U, Dikalov S, et al. Electron spin
resonance characterization of vascular xanthine and NAD(P)H oxidase
activity in patients with coronary artery disease: relation to
endothelium-dependent vasodilation. Circulation 2003;107:1383–9.
28. Tsimikas S. In vivo markers of oxidative stress and therapeutic
interventions. Am J Cardiol 2008;101:34D–42D.
29. Ky B, Burke A, Tsimikas S, et al. The influence of pravastatin and
atorvastatin on markers of oxidative stress in hypercholesterolemic
humans. J Am Coll Cardiol 2008;51:1653–62.
30. Choi SH, Chae A, Miller E, et al. Relationship between biomarkers of
oxidized low-density lipoprotein, statin therapy, quantitative coronary
angiography, and atheroma: volume observations from the REVERSAL
(Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
J Am Coll Cardiol 2008;52:24–32.
31. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine
oxidase inhibitors: renaissance half a century after the discovery of
allopurinol. Pharmacol Rev 2006;58:87–114.
32. Tsutsumi Z, Moriwaki Y, Takahashi S, Ka T, Yamamoto T. Oxidized
low-density lipoprotein autoantibodies in patients with primary gout:
effect of urate-lowering therapy. Clin Chim Acta 2004;339:117–22.
33. Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH. Oxidative
stress with an activation of the renin-angiotensin system in human
vascular endothelial cells as a novel mechanism of uric acid-induced
endothelial dysfunction. J Hypertens 2010;28:1234–42.
Key Words: allopurinol and endothelial dysfunction y coronary artery
disease y vascular oxidative stress y xanthine oxidase.
